• Listed stake divestment: Novartis AG signed a share purchase agreement with ChrysCapital to sell its stake in the listed entity Novartis India Limited, aligning with its global transformation into a pure-play innovative medicines company.
• Domestic operational footprint: The company maintains nearly 9,000 employees in India, including more than 2,000 scientists in biomedical research and over 2,500 personnel in drug development.
• Product launch pipeline: Following two innovative drug rollouts over the past two years, Novartis plans to launch another two to three innovative treatments in India over the next three years across cardiovascular, oncology, immunology, and neurosciences.
• Clinical trial activity: The company is conducting over 50 clinical trials for innovative therapies across more than 300 active sites in India, while working with the government to register its gene therapy for spinal muscular atrophy.